Resolution Therapeutics
CompanyUnited Kingdom
Resolution Therapeutics develops one asset, in phase 2 (RTX001 in end-stage liver disease). Mostly cell therapy; based in the United Kingdom.
- 1
- Asset
- Furthest stage
- Phase 2
- Raised
- £88.1M + $85M
- 1
- Trial
- 1
- Signal
Pipeline
1Engineered immune cells intended to treat end-stage liver disease.
Phase 2, Cell therapy, end-stage liver disease, cirrhosis (Phase 1)
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials1
- Funding rounds and grants10
- People6
- Signals2
- Similar companies6